This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

The cereblon E3 ligase modulator cemsidomide showed activity against multiple myeloma and two types of non–Hodgkin lymphoma in a phase I study.

Major Finding: Pharmacologic inhibition of EZH2 sensitizes preclinical models of B cell lymphoma to T-cell immunotherapy. Concept: EZH2 inhibition enhances T-cell recruitment, T-cell–B-cell ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

The ALK tyrosine kinase inhibitor (TKI) ensartinib (Ensacove; Xcovery) was approved for patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC). The decision was ...

Copyright held by the owner/author(s).

Major Finding: In breast cancer, chemotherapy elicits stronger antitumor responses when administered during estrus. Concept: The estrous cycle alters macrophage infiltration, epithelial-mesenchymal ...

For authors of Research Articles that have been declined for publication at an AACR journal, the AACR offers the corresponding author the option to easily transfer manuscript files and supporting ...

Kris Ann P. Schultz; Suzanne P. MacFarland; Melissa R. Perrino; Sarah G. Mitchell; Junne Kamihara; Alexander T. Nelson; Paige H.R. Mallinger; Jack J. Brzezinski; Kara ...

Machine learning could better stratify patients with metastatic ER-positive, HER2-negative breast cancer who are more or less likely to benefit from CDK4/6 inhibition up front. At Memorial Sloan ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.